Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!

The Immune checkpoint blockers (ICB) have greatly improved clinical outcomes in multiple cancer types and are increasingly being used in earlier disease settings alone or in combination with other therapies. However, rare but life-threatening complications defined as immune-related adverse events (irAE) as ICI-induced myocarditis can occur, justifying close monitoring and specific management [ [1] Moslehi J.J. Salem J.E. Sosman J.A. Lebrun-Vignes B. Johnson D.B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391: 933 Abstract Full Text Full Text PDF PubMed Scopus (461) Google Scholar , [2] Moslehi J.J. Johnson D.B. Sosman J.A. Myocarditis with immune checkpoint blockade. N Engl J Med. 2017; 376: 292 PubMed Google Scholar ]. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registryEuropean Journal of CancerVol. 177PreviewImmune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis. Full-Text PDF